HomepageBT3 • FRA
add
BioTime
Vorige slotkoers
€ 0,84
Dag-range
€ 0,84 - € 0,84
Jaar-range
€ 0,33 - € 1,00
Beurswaarde
230,64Â mln. USD
Gem. volume
377,00
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,50Â mln. | 4,02% |
Bedrijfskosten | 5,03Â mln. | -2,24% |
Netto inkomsten | -4,14Â mln. | 36,73% |
Netto winstmarge | -275,57 | 39,17% |
Winst per aandeel | -0,02 | 50,00% |
EBITDA | -6,34Â mln. | 2,24% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 47,90Â mln. | 9,82% |
Totale activa | 111,75Â mln. | 3,01% |
Totale passiva | 34,10Â mln. | -9,06% |
Totaal aandelenvermogen | 77,66 mln. | — |
Uitstaande aandelen | 228,36 mln. | — |
Koers-boekwaardeverhouding | 2,40 | — |
Rendement op activa | -14,46% | — |
Rendement op kapitaal | -20,40% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -4,14Â mln. | 36,73% |
Operationele kasstroom | -4,89Â mln. | 15,51% |
Kasstroom uit beleggingen | 1,90Â mln. | 5.107,89% |
Kasstroom uit financiering | 5,04Â mln. | -64,03% |
Nettomutatie in liquide middelen | 1,99Â mln. | -75,55% |
Vrije kasstroom | -2,58Â mln. | 21,63% |
Over
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Opgericht
1990
Website
Werknemers
74